Company Encyclopedia
View More
name
FT Nasdq AI & Robotics
ROBT.US
News
View More

16:42 ET Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Illumina and MyOme have announced a collaboration and strategic investment to support MyOme's clinical trial, aiming to save U.S. healthcare $200 billion annually. The partnership combines Illumina's sequencing technology with MyOme's AI-integrated risk models to advance precision medicine for early detection and prevention. The MPH trial will begin enrollment in 2026, focusing on whole-genome sequencing and risk models for chronic conditions, cancers, and rare diseases.

prnewswire·
US
ILMN
-1.15%
prnewswire·
US
ILMN
-1.15%

Illumina collaborates with MyOme with strategic investment for clinical trial, potentially saving US healthcare $200B/year.

Illumina, Inc. (NASDAQ: ILMN) and MyOme have collaborated in a partnership merging Illumina's top sequencing technology with advanced clinical genomics analyses and artificial intelligence. This alliance aims to propel precision medicine for early detection and prevention. The partnership was announced in San Diego and Menlo Park, California, on December 11, 2025.

Unusual Whales·
US
ILMN
-1.15%
Unusual Whales·
US
ILMN
-1.15%

This little-known AI software company could be the dark horse winner of the next AI supercycle starting in 2026

UiPath stock is cheap, and the company is just beginning to see its revenue growth accelerate.

MSN·
US
PATH
-3.38%
MSN·
US
PATH
-3.38%

Illumina’s AI Genomics Partnership With MyOme Might Change The Case For Investing In Illumina (ILMN)

Illumina and MyOme have announced a collaboration to support MyOme’s Proactive Health Trial, combining whole-genome sequencing with AI-integrated risk models to improve health outcomes and reduce costs. This partnership aims to enhance preventive care and rare disease diagnostics in the US healthcare system. The collaboration underscores Illumina’s focus on AI-enabled genome sequencing, despite ongoing challenges in clinical adoption, research demand, and competition. Illumina projects $4.8 billion revenue and $873.5 million earnings by 2028, with a fair value estimate of $119.84 per share, reflecting an 11% downside to its current price.

Simplywall·
US
ILMN
-1.15%
Simplywall·
US
ILMN
-1.15%

Is IBM the Top Tech Stock to Buy for 2026?

Is IBM the Top Tech Stock to Buy for 2026?

Barchart Option·
US
IBM
-0.48%
Barchart Option·
US
IBM
-0.48%
© 2025 Longbridge｜Disclaimer